Departments of Obstetrics and Gynecology and
Clinical Epidemiology, Biostatistics, and Bioinformatics, and.
Am J Clin Nutr. 2017 Sep;106(3):812-820. doi: 10.3945/ajcn.117.158931. Epub 2017 Aug 9.
Hyperemesis gravidarum (HG) leads to dehydration, poor nutritional intake, and weight loss. HG has been associated with adverse pregnancy outcomes such as low birth weight. Information about the potential effectiveness of treatments for HG is limited. We hypothesized that in women with HG, early enteral tube feeding in addition to standard care improves birth weight. We performed a multicenter, open-label randomized controlled trial [Maternal and Offspring outcomes after Treatment of HyperEmesis by Refeeding (MOTHER)] in 19 hospitals in the Netherlands. A total of 116 women hospitalized for HG between 5 and 20 wk of gestation were randomly allocated to enteral tube feeding for ≥7 d in addition to standard care with intravenous rehydration and antiemetic treatment or to standard care alone. Women were encouraged to continue tube feeding at home. On the basis of our power calculation, a sample size of 120 women was anticipated. Analyses were performed according to the intention-to-treat principle. Between October 2014 and March 2016 we randomly allocated 59 women to enteral tube feeding and 57 women to standard care. The mean ± SD birth weight was 3160 ± 770 g in the enteral tube feeding group compared with 3200 ± 680 g in the standard care group (mean difference: -40 g, 95% CI: -230, 310 g). Secondary outcomes, including maternal weight gain, duration of hospital stay, readmission rate, nausea and vomiting symptoms, decrease in quality of life, psychological distress, prematurity, and small-for-gestational-age, also were comparable. Of the women allocated to enteral tube feeding, 28 (47%) were treated according to protocol. Enteral tube feeding was discontinued within 7 d of placement in the remaining women, primarily because of its adverse effects (34%). In women with HG, early enteral tube feeding does not improve birth weight or secondary outcomes. Many women discontinued tube feeding because of discomfort, suggesting that it is poorly tolerated as an early routine treatment of HG. This trial was registered at www.trialregister.nl as NTR4197.
妊娠剧吐(HG)可导致脱水、营养摄入不良和体重减轻。HG 与不良妊娠结局相关,如低出生体重。有关治疗 HG 的疗效的信息有限。我们假设在 HG 妇女中,早期肠内管饲加标准治疗可改善出生体重。我们在荷兰的 19 家医院进行了一项多中心、开放标签、随机对照试验[通过再喂养治疗妊娠剧吐的母婴结局(MOTHER)]。共纳入 116 名妊娠 5 至 20 周因 HG 住院的妇女,随机分配接受肠内管饲≥7 天加静脉补液和止吐治疗的标准治疗,或仅接受标准治疗。鼓励妇女在家继续进行管饲。根据我们的效能计算,预计需要 120 名妇女的样本量。分析按照意向治疗原则进行。2014 年 10 月至 2016 年 3 月,我们随机分配 59 名妇女接受肠内管饲,57 名妇女接受标准治疗。肠内管饲组的平均出生体重为 3160 ± 770g,而标准治疗组为 3200 ± 680g(平均差异:-40g,95%CI:-230,310g)。次要结局,包括产妇体重增加、住院时间、再入院率、恶心和呕吐症状、生活质量下降、心理困扰、早产和小于胎龄儿,也相似。在接受肠内管饲的妇女中,28 名(47%)按方案治疗。其余妇女的肠内管饲在放置后 7 天内停止,主要是因为其不良反应(34%)。在 HG 妇女中,早期肠内管饲并不能改善出生体重或次要结局。许多妇女因不适而停止管饲,这表明它作为 HG 的早期常规治疗方法耐受性较差。该试验在 www.trialregister.nl 上注册为 NTR4197。